Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06940180 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Toripalimab With Chemotherapy for Sinus Cancer

StatusRecruiting
PhasePhase 2
Started2025-06-17
View on ClinicalTrials.gov ↗

Amendment history

2026-08-28
Study Status, Sponsor/Collaborators, Contacts/Locations v3
Sponsor changed: Glenn J. Hanna → Dana-Farber Cancer Institute+14 characters
WasGlenn J. Hanna
NowDana-Farber Cancer Institute
Study sitescontacts updated at 2 of 2 sites
2025-06-25
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-10→confirmed 2025-06-17
Study sitesdetails revised at 2 of 2 sites
2025-04-22
Study Status, Outcome Measures v1
Secondary endpoints7 entries, revised
Incidence of Adverse Events [Safety and tolerabilityTolerability]
2025-04-15
Original filing
The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers. The names of the study drugs used in this research study are: * Toripalimab (a type of monoclonal antibody) * Carboplatin (a type of antineoplastic agent) * Docetaxel (a type of antineoplastic agent) * Cisplatin (a type of antineoplastic agent)
Trial Details
NCT Number NCT06940180
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Coherus Oncology, Inc.
Conditions Sinonasal Cancer, Paranasal Sinus Neoplasms, Squamous Cell Carcinoma, Sinonasal Undifferentiated Carcinoma, Locally Advanced Head and Neck Cancer
Enrollment 20 participants
Start Date 2025-06-17
Primary Completion 2028-02-01 (estimated)
Study Completion 2029-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-31